EUVIMEDEUVIMED entdecken
Multizentrische Studie

MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients

Stefanie Jilg iD, Juliana Schwaab, Katja Sockel, Carl C Crodel, Valeska Brueckl, Frank Stegelmann, Madlen Jentzsch iD, Daniel Sasca, Margarete Moyses, Stephan Fuhrmann, Daniel Gundel, Madlen Caduc und 4 weitere

Annals of Hematology · 2024-10 · 103 (10) · 4065-4077

DOI: 10.1007/s00277-024-05908-4 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Hematology, online erschienen am 29.07.2024. Verfasst von Stefanie Jilg und 15 weiteren Autor:innen. Beteiligte Einrichtung: Onkologie Erding, Bajuwarenstr.3, Erding, Germany. stefanie.jilg@onkologie-erding.de. Hauptthemen laut MEDLINE: Primary Myelofibrosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisHumansMaleFemaleAgedMiddle AgedRetrospective StudiesPyrimidinesAged, 80 and overBenzamidesTreatment OutcomeJanus Kinase 2AdultJanus Kinase 1Pyrazines

Stichwörter der Autor:innen

AnemiaMoReLifeMomelotinibMyelofibrosisThrombocytopenia

Substanzen

PyrimidinesBenzamides4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamideJanus Kinase 2JAK2 protein, humanJanus Kinase 1Pyrazines

Autor:innen und Institutionen

  • Onkologie Erding, Bajuwarenstr.3, Erding, Germany. stefanie.jilg@onkologie-erding.de.
  • Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. stefanie.jilg@onkologie-erding.de.
  • Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.
  • Medical Clinic and Policlinic I, University Hospital Dresden, TU Dresden, Dresden, Germany.
  • Abteilung Hämatologie und Internistische Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
  • Department of Hematology and Oncology, University Hospital Erlangen, Friedrich- Alexander-University Erlangen-Nürnberg, Erlangen, Germany.

ORCID-Profile: Stefanie Jilg, Madlen Jentzsch, Florian Heidel, Petro E Petrides

Zitieren

APA

Jilg, S., Schwaab, J., Sockel, K., Crodel, C. C., Brueckl, V., Stegelmann, F., Jentzsch, M., Sasca, D., Moyses, M., Fuhrmann, S., Gundel, D., Caduc, M., Teichmann, L. L., Heidel, F., Al-Ali, H. K., & Petrides, P. E. (2024). MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients. Annals of Hematology, 103(10), 4065-4077. https://doi.org/10.1007/s00277-024-05908-4

Vancouver

Jilg S, Schwaab J, Sockel K, Crodel CC, Brueckl V, Stegelmann F, et al. MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients. Annals of Hematology. 2024;103(10):4065-4077. doi:10.1007/s00277-024-05908-4

BibTeX
@article{Jilg2024,
  author = {Jilg, Stefanie and Schwaab, Juliana and Sockel, Katja and Crodel, Carl C and Brueckl, Valeska and Stegelmann, Frank and Jentzsch, Madlen and Sasca, Daniel and Moyses, Margarete and Fuhrmann, Stephan and Gundel, Daniel and Caduc, Madlen and Teichmann, Lino L and Heidel, Florian and Al-Ali, Haifa K and Petrides, Petro E},
  title = {MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients},
  journal = {Annals of Hematology},
  year = {2024},
  volume = {103},
  number = {10},
  pages = {4065--4077},
  doi = {10.1007/s00277-024-05908-4}
}
Kostenlos starten →